Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

AYTU BIOPHARMA, INC

AYTU · Nasdaq · CIK 0001385818 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
0 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2025-06-09 · Disbrow Jarrett · $25.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Disbrow Joshua R.Chief Executive Officer
○
PYSZCZYMUKA GREGChief Commercial Officer
○
Disbrow JarrettChief Business Officer
○
Selhorn Ryan JChief Financial Officer
○
LIU VIVIAN HDirector
○
JAIN ABHINAVDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-06-09 · Disbrow Jarrett.

Recent Form 4 activity

0Purchases
0Sales
8Other Form 4 lines
8SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-1.0%
3M
-10.5%
6M
-25.1%
12M
-21.5%

Volatility & liquidity

Volatility
90.2%
Beta
—
Avg daily value
USD 68,042

Valuation

Market cap
USD 21.4M
P/E
—

Fundamentals

Profit margin
-24.8%
ROE
-40.4%
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-12 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2026-06-30 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-09-15 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
345,229
Previous report
311,607
Avg daily volume
72,778
Days to cover
4.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-06-09Disbrow Joshua R.Purchase (P)Common Stock66,666USD 1.50USD 99,999SEC filing ↗
2025-06-09Disbrow JarrettPurchase (P)Common Stock16,666USD 1.50USD 24,999SEC filing ↗
2025-02-28Disbrow Joshua R.Purchase (P)Common Stock15,000USD 1.30USD 19,500SEC filing ↗
2023-06-16PYSZCZYMUKA GREGPurchase (P)Common Shares12,000USD 1.87USD 22,440SEC filing ↗
2023-06-14Disbrow Joshua R.Purchase (P)Common Shares14,000USD 1.86USD 26,040SEC filing ↗
2022-12-19PYSZCZYMUKA GREGPurchase (P)Common Stock100,000USD 0.24USD 24,000SEC filing ↗
2022-12-19Disbrow Joshua R.Purchase (P)Common Stock112,371USD 0.22USD 24,722SEC filing ↗
2022-11-18Oki Mark KPurchase (P)Common Shares90,000USD 0.23USD 20,700SEC filing ↗
2022-11-18Disbrow Joshua R.Purchase (P)Common Shares222,000USD 0.24USD 53,280SEC filing ↗
2020-12-11ARMISTICE CAPITAL, LLC; Armistice Capital Master Fund Ltd.; Boyd StevenPurchase (P)Common Stock1,333,334USD 6.00USD 8,000,004SEC filing ↗
2020-11-18DOCKERY CARLPurchase (P)Common Shares10,000USD 0.92USD 9,200SEC filing ↗

Form 4 evidence

8 transaction lines in the latest 365-day window; 99 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-28Selhorn Ryan JAward / grant (A)Common Stock25,000USD 0.00USD 0SEC filing ↗
2026-07-28PYSZCZYMUKA GREGAward / grant (A)Common Stock20,000USD 0.00USD 0SEC filing ↗
2026-07-28LIU VIVIAN HAward / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (8 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-28Selhorn Ryan JAward / grant (A)Common Stock25,000USD 0.00USD 0SEC filing ↗
2026-07-28PYSZCZYMUKA GREGAward / grant (A)Common Stock20,000USD 0.00USD 0SEC filing ↗
2026-07-28LIU VIVIAN HAward / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
2026-07-28JAIN ABHINAVAward / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
2026-07-28Donofrio John Jr.Award / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
2026-07-28Disbrow Joshua R.Award / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-07-28Disbrow JarrettAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-07-28DOCKERY CARLAward / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAYTU
CIK0001385818
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history99 transaction lines from 2020-01-21 to 2026-07-28
12 P purchase lines · 7 S sale lines · 80 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.